Sarepta Stock Tumbles 30% Amid Concerns Over Gene Therapy’s Future

Sarepta Stock Tumbles 30% Amid Concerns Over Gene Therapy's Future

The stock value of Sarepta Therapeutics plummeted by over 30% on Friday, reflecting increased threats to its gene therapy product's prospects.

Sources familiar with the situation informed CNBC that the U.S. Food and Drug Administration is expected to request that Sarepta halts the distribution of its gene therapy, Elevidys, on a voluntary basis.

Separately, FDA Commissioner Marty Makary indicated that the organization is reassessing whether Sarepta's gene therapy should remain in the market, amidst existing uncertainties.

This follows an FDA investigation into two fatalities linked to Elevidys. Additionally, Sarepta has reported another death associated with a distinct investigational gene therapy.

At the time of reporting, Sarepta has not released any official statement or response.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts